Crisil rating lifts Bafna Pharma

The stock of Bafna Pharmaceuticals jumped 5.77 per cent at ₹33 on the BSE after Crisil upgraded its short-term and long-term ratings in respect of total bank facilities. The rating agency has upgraded the rating to Crisil BB-/stable (from Crisil D) for the long term and Crisil A4+ (from Crisil D) for the short term. Instruments with this rating are considered to have minimal degree of safety regarding timely payment of financial obligations.